Fecal Microbiome Transplant Converts Melanoma Immunotherapy Non-Responders into Responders

Scientists at the NIH in collaboration with UPMC Hillman Cancer Center have shown how some patients with advanced melanoma that hasn’t responded to immune checkpoint inhibitor therapy, can be converted to immunotherapy responders by giving them a fecal microbiota transplant, taken from patients who had responded very well to immunotherapy. Results from the proof-of-principle Phase II study suggest that introducing certain fecal microorganisms into a patient’s colon may help individuals respond to immune checkpoint inhibitor drugs.